LIBRETTO-001 is an open-label phase I/II, single-arm study of selpercatinib in RET-dependent cancers; the 2025 final analysis reports efficacy and safety in RET-fusion-positive NSCLC. Here, RET is linked to non-small cell lung carcinoma.